Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T07:01:05.395Z Has data issue: false hasContentIssue false

Monoamine oxidase inhibitor efficacy in depression and the ‘cheese effect’1

Published online by Cambridge University Press:  09 July 2009

Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Copyright
Copyright © Cambridge University Press 1981

References

Baldessarini, R. J. (1975). The basis for amine hypotheses in affective disorders. Archives of General Psychiatry 32, 10871093.CrossRefGoogle ScholarPubMed
Elsworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lees, A. J., Phuapradit, P., Shaw, K. M. & Kumar, P. (1978). Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology 57, 3338.CrossRefGoogle Scholar
Escobar, J. A., Schiele, B. C. & Zimmerman, R. (1974). The tranylcypromine isomers: a controlled clinical trial. American Journal of Psychiatry 131, 10251026.CrossRefGoogle ScholarPubMed
Fuentes, J. A., Oleshansky, M. A. & Neff, N. H. (1976). Comparison of the apparent antidepressant activity of (–) and (+) tranylcypromine in an animal model. Biochemical Pharmacology 25, 801804.CrossRefGoogle ScholarPubMed
Gelenberg, A. J., Wojcik, J. D., Growdon, J. H., Sved, A. F. & Wurtman, R. J. (1980). Tyrosine for the treatment of depression. American Journal of Psychiatry 137, 622623.Google ScholarPubMed
Glover, V., Elsworth, J. D. & Sandler, M. (1980). Dopamine oxidation and its inhibition by (–)-deprenyl in man. Journal of Neural Transmission Suppl. 16, 163172.CrossRefGoogle Scholar
Goldberg, I. K. (1980). l-Tyrosine in depression. Lancel ii, 364.CrossRefGoogle Scholar
Johnston, J. P. (1968). Some observations upon a new inhibitor of monoamine oxidase. Biochemicai Pharmnacology 17, 12851297.CrossRefGoogle ScholarPubMed
Joshi, V. G. (1976). Isoniazid (I.N.H.) in the treatment of depressive syndrome: a pilot trial. Diseases of the Nervous System 37, 100111.Google ScholarPubMed
Knoll, J. (1976). Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In Monoamine Oxidase and its Inhibition (ed. Wolstenholme, G. E. W. and Knight, J.), pp. 135161. Elsevier–Excerpta Medica–North Holland: Amsterdam.Google Scholar
Knoll, J. & Magyar, K. (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. In Monoamine Oxidases — New Vistas (ed. Costa, E. and Sandler, M.), pp. 393408. Raven Press: New York.Google Scholar
Lee, K. Y., Beilin, J. L. & Vandongen, R. (1979). Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin. Loncet i, 11101111.CrossRefGoogle Scholar
Lejonc, J. L., Gusmini, D. & Brochard, P. (1979). Isoniazid and reaction to cheese. Annals of Internal Medicine 91, 793.Google ScholarPubMed
Lipper, S., Murphy, D. L., Slater, S. & Buchsbaum, M. S. (1979). Comparative behavioral effects of clorgyline and pargyline in man. A preliminary evaluation. Psychopharmacology 62, 123128.CrossRefGoogle ScholarPubMed
Lovenberg, W., Weissbach, H. & Udenfriend, S. (1962). Aromatic l-amino acid decarboxylase. Journal of Biological Chemistry 237, 8993.CrossRefGoogle ScholarPubMed
Mann, J. & Gershon, S. (1980). l-Deprenyl, a selective monoamine oxidase type B inhibitor in endogenous depression. Life Sciences 26, 877882.CrossRefGoogle ScholarPubMed
Melamed, E., Hefti, F. & Wurtman, R. J. (1980). Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. Proceedings of National Academy of Sciences, U.S.A. 77, 43054309.CrossRefGoogle ScholarPubMed
Mendis, N., PareC, M. B. C, M. B., Sandler, M., Glover, V. & Stern, G. M. (1981). Is the failure of (–)-deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to its freedom from the ‘cheese effect’? Psychopharmacology (in the press).CrossRefGoogle Scholar
Morgan, J. P. (1980). Isoniazid and levodopa. Annals of Internal Medicine 92, 434.CrossRefGoogle ScholarPubMed
Murphy, D. L., Lipper, S., Pickar, D., Jimerson, D., Cohen, R. M., Garrick, N. A., Alterman, S. & Campbell, I. C. (1981). Selective inhibition of monoamine oxidase type A:clinical antidepressant effects and metabolic changes in man. In Monoamine Oxidase Inhibitors – The Stale of the Art (ed. Youdim, M. B. H. and Paykel, E. S.), pp. 189205. Wiley: Chichester.Google Scholar
Pare, C. M. B. & Sandler, M. (1959). A clinical and biochemical study of a trial of iproniazid in the treatment of depression. Journal of Neurology, Neurosurgery and Psychiatry 22, 247251.Google ScholarPubMed
Pickar, D., Cohen, R. M., Murphy, D. L. & Fried, D. (1979). Tyramine infusions in bipolar illness: behavioral effects and longitudinal changes in pressor sensitivity. American Journal of Psychiatry 136, 14601463.Google ScholarPubMed
Reigle, T. G., Orsulak, P. J., Avni, J., Platz, P. A. & Schildkraut, J. J. (1980). The effects of tranylcypromine isomers on norepinephrine-H3 metabolism in rat brain. Psychopharmacology 69, 193199.CrossRefGoogle ScholarPubMed
Reynolds, G. P., Elsworth, J. D., Blau, K., Sandler, M., Lees, A. J. & Stern, G. M. (1978). Deprenyl is metabolized to methamphetamine and amphetamine in man. British Journal of Clinical Pharmacology 6, 542544.CrossRefGoogle ScholarPubMed
Reynolds, G. P., Rausch, W.-D. & Riederer, P. (1980 a). Effects of tranylcypromine stereoisomers on monoamine oxidation in man. British Journal of Clinical Pharmacology 9, 521523.CrossRefGoogle ScholarPubMed
Reynolds, G. P., Riederer, P. & Rausch, W.-D. (1980 b). Dopamine metabolism in human rain: effects of monoamine oxidase inhibition in vitro by (–)-deprenyl and (+) and (–) tranylcypromine. Journal of Neural Transmission Suppl. 16, 173178.CrossRefGoogle Scholar
Robinson, D. S., Lovenberg, W., Keiser, G. & Sjoerdsma, A. (1968). Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochemical Pharmacology 17, 109119.CrossRefGoogle ScholarPubMed
Sacks, W., Vogel, W. H., Nagatsu, T., Lloyd, K. G. & Sandler, M. (1979). Is there DOPA decarboxylase in human brain? In Catecholamines: Basic and Clinical Frontiers Vol. 1 (ed. Usdin, E., Kopin, I. J. and Barchas, J.), pp. 127131. Pergamon Press: New York.CrossRefGoogle Scholar
Salzer, H. M. & Lurie, M. L. (1963). Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). Archives of Neurology and Psychiatry 70, 317324.CrossRefGoogle Scholar
Sandler, M., Ruthven, C. R. J., Goodwin, B. L., Reynolds, G. P., Rao, V. A. R. & Coppen, A. (1979). Deficient production of tyramine and octopamine in cases of depression. Nature (London) 278, 357358.CrossRefGoogle ScholarPubMed
Sandler, M., Glover, V., Ashford, A. & Esmail, A. (1980). The inhibition of tyramine oxidation and the tyramine hypertensive response (‘cheese effect’) may be independent phenomena. Journal of Neural Transmission 48, 241247.CrossRefGoogle ScholarPubMed
Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry 122, 509522.CrossRefGoogle ScholarPubMed
Singer, T. P., von, Korif R. W. & Murphy, D. L. (eds.) (1979). Monoamine Oxidase: Structure, Function and Altered Functions. Academic Press: New York.Google Scholar
Smith, C. K. & Durack, D. T. (1978). Isoniazid and reaction to cheese. Annals of Internal Medicine 91, 793.Google Scholar
Squires, R. F. (1972). Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. In Monoamine Oxidases – New Vistas (ed. Costa, E. and Sandler, M.), pp. 355370. Raven Press: New York.Google Scholar
Tringer, L., Haits, G. & Varga, E. (1971). The effect of (–) phenyliso-propyl-methyl-propinylamine HCI in depressions.In Proceedings of Hungarian Vth Pharmacological Conference (ed. Leszkovszky, G. P.), pp. 111114. Publishing House of the Hungarian Academy of Sciences: Budapest.Google Scholar
Varga, E. & Tringer, L. (1967). Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCI, E-250). Acta medica academiae Scientiarum hungaricae 23, 289295.Google Scholar
Weil-Malherbe, H., Axelrod, K. & Tomchick, R. (1959). Blood-brain barrier for adrenaline. Science 129, 12261227.CrossRefGoogle ScholarPubMed